Comparison
Lanreotid vs. Terlipressin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
108736-35-2
14636-12-5
Molecular weight
1096.34 g/mol
1227.37 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Terlipressin
Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
1
0
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Lanreotid and Terlipressin?
- Lanreotid is classified as "Research other", while Terlipressin is classified as "Research other". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or Terlipressin?
- The highest available evidence level is "Human RCT" for Lanreotid and "Human RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and Terlipressin in Germany and the United States?
- Germany: Lanreotid — Prescription, Terlipressin — Prescription. United States: Lanreotid — Prescription, Terlipressin — Prescription. These are factual summaries with source and review date on the individual pages.